scholarly journals Long-term follow-up of patients with paroxysmal atrial fibrillation and severe left atrial scarring: comparison between pulmonary vein antrum isolation only or pulmonary vein isolation combined with either scar homogenization or trigger ablation

EP Europace ◽  
2016 ◽  
Vol 19 (11) ◽  
pp. 1790-1797 ◽  
Author(s):  
Sanghamitra Mohanty ◽  
Prasant Mohanty ◽  
Luigi Di Biase ◽  
Chintan Trivedi ◽  
Eli Hamilton Morris ◽  
...  
Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Isabel Deisenhofer ◽  
Tilko Reents ◽  
Heidi L Estner ◽  
Stephanie Fichtner ◽  
Christian von Bary ◽  
...  

Introduction: Segmental pulmonary vein isolation (PVI) leads to elimination of paroxysmal atrial fibrillation (AF) in approximately 75% of patients. Ablation of complex fractionated atrial electrograms (CFAE) is an alternative ablation strategy. In this prospective randomized study the long-term effect of PVI alone is compared to the effect of combined PVI and CFAE ablation in paroxysmal AF. Methods: 98 patients with paroxysmal AF (57±10 years, 74 male) were randomly assigned to PVI (48 patients) or PVI+CFAE ablation (50 patients). Additional CFAE ablation was performed in the PVI+CFAE group if AF was still inducible after PVI. Follow-up results were assessed with repetitive 7 days Holter ECG and clinical evaluation including repeat ablations. Results: Additional CFAE ablation was performed in 30/50 (60%) patients of the PVI+CFAE group with still inducible AF after PVI. In each group, 2 patients were lost to long term follow-up. In the intention-to-treat analysis at 3 months and after 19±8 months, there was no significant difference between both groups (36/48 [75%] and 34/46 [74%] patients in the PVI and 37/50 [73%] and 40/48 [83%] of patients in the PVI+CFAE ablation group in sinus rhythm [p=0.32]). In subgroup analysis, patients actually treated with the combined PVI+CFAE ablation approach had a significantly better long-term success (25/28; 89%) than patients with still inducible AF who underwent PVI only (22/30;73%; p=0.02). In both groups repeat ablations were performed in 31% (PVI group; 15/48 patients) and 35% (PVI+CFAE group; 17/48 patients) (p=n.s). After 9 months, significantly more patients in the PVI+CFAE group experienced sustained regular atrial tachycardia than in the PVI group (6/44 versus 1/39 patients, P=0.02). Conclusion: The combination of PVI and CFAE ablation was equally effective than PVI alone in reaching freedom of AF in the intention-to-treat analysis. During long-term follow-up, patients actually treated with combined PVI+CFAE ablation had a significantly better outcome (89% vs. 73%). However, the rate of ablation-induced regular atrial tachycardias is inreased.


2008 ◽  
Vol 51 (8) ◽  
pp. 850-855 ◽  
Author(s):  
Wendel Moreira ◽  
Randy Manusama ◽  
Carl Timmermans ◽  
Benoit Ghaye ◽  
Suzanne Philippens ◽  
...  

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
D Musat ◽  
N Milstein ◽  
R Shaw ◽  
A Bhatt ◽  
M Preminger ◽  
...  

Abstract Background Cryoballoon (CB) pulmonary vein isolation (PVI) is increasingly being used in patients (pts) with persistent atrial fibrillation (AF). However, there are limited data about the pattern of atrial fibrillation (AF) recurrence in these pts. Objective To assess, using an implantable loop recorder (ILR), the patterns of AF recurrence following CB PVI in pts with persistent atrial fibrillation. Methods We enrolled consecutive pts with persistent AF ablation undergoing their first CB ablation. Other cavotricuspid isthmus ablation when indicated, no other ablation was performed. A Reveal LINQ ILR (Medtronic) was implanted <3 months following ablation; all pts had a minimum of 1-year follow-up. The recurrence of any atrial arrhythmia was determined and adjudicated; 4 distinct AF patterns were characterized (Figure). Results We studied 64 pts (66±9 years; 50 [78%] male; CHA2DS2-VASc 2.6±1.9) with persistent AF; 52 (81%) pts were on an antiarrhythmic drug (AAD) peri-ablation. During 803±361 days of follow-up, 33 (52%) pts had their 1st AF recurrence 91–365 days post-ablation and another 17 (27%) pts had their 1st AF recurrence >365 days post-ablation. No AF was seen in 14 (31%) pts. Most pts (33 of 50, 66%) with AF recurrence presented with 1 of 3 distinct patterns of paroxysmal AF (Figure), which ranged from 22 min to 124 hours. In 2/3 of these pts, all AF recurrences lasted <24 hours. Only 17 (34%) pts recurred with persistent AF. Conclusion Following single CB PVI, most pts with persistent AF remained free of persistent AF during long-term follow-up. Most pts with recurrent AF have 1 of 3 distinct patterns with episodes commonly last <24 hours. These data suggest that CB PVI ablation may halt AF progression in pts initially presenting with persistent AF.


2021 ◽  
Author(s):  
Ruzica Jurcevic ◽  
Lazar Angelkov ◽  
Velibor Ristic ◽  
Dejan Vukajlovic ◽  
Petar Otasevic ◽  
...  

Abstract Purpose Pulmonary vein isolation (PVI) is the most effective treatment strategy for atrial fibrillation (AF). This study evaluated Pulmonary Vein Isolation Outcome Degree (PVIOD) as a new semi-quantitative measure for PVI success after a 7-year follow-up and determined predictors associated with PVIOD.Methods We enrolled 117 patients with symptomatic AF who underwent PVI and after a 7-year follow-up applied PVIOD with 4 possible outcomes. PVIOD 1 group included patients with successful single PVI. PVIOD 2 group included patients with efficacy after ≥ 2 re-PV isolation and/or additional substrate modification (ASM). PVIOD 3 group contained subjects with clinical success after PVI±ASM. Patients with procedural and clinical failure were in PVIOD 4 group.Results In multivariate ordinal logistic regression analysis PVIOD was independently associated with longstanding persistent AF with paroxysmal AF as referent category: odds ratio (OR) 4.1, 95% confidence interval (95% CI) 1.3-12.8 (P=0.014), left atrial (LA) diameter: OR 1.2, 95% CI 1.1-1.3 (P<0.001) and CHA2DS2-VASc score: OR 1.5, 95% CI 1.0-2.2 (P=0.039). LA size, CHA2DS2-VASc score and AF type predicted 7-year probability for procedural and procedural with clinical failure. LA diameter >41mm (AUC 0.741, 95% CI 0.6-0.8, P<0.001) and CHA2DS2-VASc score ≥2 (AUC 0.718, 95% CI 0.6-0.8, P<0.001) predicted long-term procedural and clinical failure. Conclusion PVIOD is a new classification for PVI success. LA diameter, CHA2DS2-VASc score and AF type are independently associated with PVIOD and predict procedural and procedural with clinical failure after the 7-year follow-up. LA diameter >41mm and CHA2DS2-VASc score ≥2 predict long-term PVI failure.


Sign in / Sign up

Export Citation Format

Share Document